Correction: Serum Iron Levels and the Risk of Parkinson Disease: A Mendelian Randomization Study
Year: 2013
Type: erratum
Abstract: Background: Although levels of iron are known to be increased in the brains of patients with Parkinson disease (PD), epidemiological evidence on a possible effect of iron blood levels on PD risk is inconclusive, with effects reported in opposite directions.Epidemiological studies suffer from problems of confounding and reverse causation, and mendelian randomization (MR) represents an alternative approach to provide unconfounded estimates of the effects of biomarkers on disease.We performed a MR study where genes known to modify iron levels were used as instruments to estimate the effect of iron on PD risk, based on estimates of the genetic effects on both iron and PD obtained from the largest sample meta-analyzed to date. Methods and Findings:We used as instrumental variables three genetic variants influencing iron levels, HFE rs1800562, HFE rs1799945, and TMPRSS6 rs855791.Estimates of their effect on serum iron were based on a recent genome-wide metaanalysis of 21,567 individuals, while estimates of their effect on PD risk were obtained through meta-analysis of genomewide and candidate gene studies with 20,809 PD cases and 88,892 controls.Separate MR estimates of the effect of iron on PD were obtained for each variant and pooled by meta-analysis.We investigated heterogeneity across the three estimates as an indication of possible pleiotropy and found no evidence of it.The combined MR estimate showed a statistically significant protective effect of iron, with a relative risk reduction for PD of 3% (95% CI 1%-6%; p = 0.001) per 10 mg/dl increase in serum iron.Conclusions: Our study suggests that increased iron levels are causally associated with a decreased risk of developing PD.Further studies are needed to understand the pathophysiological mechanism of action of serum iron on PD risk before recommendations can be made.
Source: PLoS Medicine
Authors: Irene Pichler, Fabiola Del Greco M., Martin Gögele, Christina M. Lill, Lars Bertram, Chuong B. Do, Nicholas Eriksson, Tatiana Foroud, Richard H. Myers, Michael Nalls, Margaux F. Keller, Beben Benyamin, John B. Whitfield, Peter P. Pramstaller, Andrew A. Hicks, John R. Thompson, Cosetta Minelli
Institutions: Imperial College London, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Max Planck Institute for Molecular Genetics, 23andMe (United States), Indiana University School of Medicine, Boston University, National Institutes of Health, National Institute on Aging, Temple University, The University of Queensland, QIMR Berghofer Medical Research Institute, Ospedale di Bolzano, University of Lübeck, University of Leicester
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,460
Funders: U.S. Department of Defense, U.S. Department of Health and Human Services, Michael J. Fox Foundation for Parkinson's Research, Susan G. Komen for the Cure, American Association for the Advancement of Science, American Parkinson Disease Association, Cure Alzheimer's Fund, University of Rochester, University of Dundee, Queen Mary University of London, South London and Maudsley NHS Foundation Trust, Prize4Life, London School of Hygiene and Tropical Medicine, National Alliance for Research on Schizophrenia and Depression, Wellcome Trust, National Institute for Health and Care Research, Parkinson's UK, King's College London, University College London, University of Oxford, Cardiff University, Trinity College Dublin, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Radboud Universiteit, Vrije Universiteit Amsterdam, Bundesministerium für Bildung und Forschung, Erasmus Medisch Centrum, Centre National de la Recherche Scientifique, Deutsches Zentrum für Neurodegenerative Erkrankungen, Tartu Ülikool, Hersenstichting, Moorfields Eye Hospital NHS Foundation Trust, Provincia autonoma di Bolzano - Alto Adige, National Institutes of Health, EMD Serono, Fidelity Biosciences, Medical Research Council, Cambridge Institute for Medical Research, University of Cambridge, Diamantina Institute, University of Queensland, National Institute on Aging, National Human Genome Research Institute, National Institute of Neurological Disorders and Stroke, National Institute of Environmental Health Sciences, National Center for Research Resources, NIH Clinical Center
Awards: G226565915, Verbundprojekt: Nationales Genomforschungsnetz 2: Systematisch-Methodische Plattform GEM: Standort Kiel: PopGen: Populationsrepräsentative Biobank Schleswig-Holstein, G2845388095, Prospective studies on Parkinson's disease, Washington University Center for Translational Neuroscience, G4119534169, G4265316335, Verbundprojekt Funktionelle Genomik der Parkinson-Erkrankung : Genomik, funktionelle Analyse und Bioinformatik (Teilprojekt 1, TP2, TP8, TP9, TP10, TP12, TP16), NEURON-Verbund: Identifikation von Genen, die familiäre Formen der Parkinson Erkrankung verursachen, Teilprojekt 1, G4721042799, Characterization of the role of cyclin G-associated kinase in Parkinson disease, Mentorship Program Patient-Oriented Research on Aging, G7310981802, Washington University Institute of Clinical and Translational Sciences (UL1), REFUND CHECK AND WAS DE-OBLIGATED IN THE AMOUNT OF $28,044., Genome wide SNP analysis in Parkinson's disease, G9000060582
OpenAlex ID: W1994094512
